Legend Biotech
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 1 week.
- Its last 6 Sell calls were actually followed by a +6% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -36.4% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 6.1% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation C
How expensive the stock is versus earnings, sales and its own 5-year history.
| Forward P/E | 26.5x | Better than 22% |
| Price / Sales | 2.5x | Better than 49% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability C-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 60.3% | Better than 75% |
| Operating margin | -13.3% | Better than 14% |
| Net margin | -28.8% | Better than 11% |
| Return on equity | -29.1% | Better than 13% |
| Return on invested capital | -22.1% | Better than 12% |
Momentum D-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -30.1% | Better than 18% |
| 6-month return | -48.1% | Better than 8% |
| 12-month return (ex latest month) | -32.9% | Better than 7% |
| Distance below 52-week high | 59.3% | Better than 11% |
Financial Health C
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.0x | Better than 55% |
| Debt to assets | 23.9% | Better than 50% |
| Interest coverage | -12.2x | Better than 12% |
Analyst View B+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 60.0% | Better than 36% |
| Upside to average target | 174.8% | Better than 93% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 16.10
- Open
- 15.95
- Day range
- 15.15 - 16.13
- Avg price
- 15.48
- Volume
- 3.42M
- Turnover
- 52.99M
- Turnover ratei
- 3.76%
- Volume ratioi
- 1.27
- Amplitudei
- 6.12%
- 52-week rangei
- 15.15 - 37.50
Valuation
- P/Ei
- -9.41
- P/E (TTM)i
- -762.50
- P/Bi
- 2.33
- EPSi
- -1.62
- Book value / shi
- 6.54
- Net profit
- -314.23M
- Net assets
- 1.27B
Share structure
- Market cap
- 2.96B
- Float capi
- 1.39B
- Shares out
- 193.97M
- Float sharesi
- 91.01M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2020-06-05
59.3% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-21.05M net over the window
Short interest
- Shares short
- 11.90M
- % of floati
- 6.12%
- Days to coveri
- 6.29
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Legend Biotech (LEGN)?
Legend Biotech last traded at 15.25. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Legend Biotech's market cap?
About 2.96B.
What is the P/E ratio of Legend Biotech?
The trailing twelve-month P/E is -762.50. The Valuation tab shows it against the stock's own five-year range.
Does Legend Biotech pay a dividend?
Legend Biotech does not currently pay a regular dividend.
Is Legend Biotech a buy according to analysts?
The consensus of 10 analysts is a Buy rating, with an average 12-month price target of 41.90, which implies 174.8% upside from the current price. This is not investment advice.
What is Legend Biotech's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Legend Biotech a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.
Legend Biotech discussion 0 comments